Day 2. Saturday, 27 November 2021
|
|
Time
|
Title
|
Speakers
|
|
8am - 8.20am
|
Session 1: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary: Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).
|
Dr. Arwa Isameldin Ahmed
Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar.
|
|
8.20am - 8.40am
|
Session 2: Gastrointestinal Cancer - Colorectal and Anal: Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
|
Dr. Kakil Ibrahim
Sr. Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
8.40am - 9.00am
|
Session 3: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary: Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577.40 Ronan Joseph Kelly, MBA, MD
|
Dr. Alaaeldin Shablak
Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
9.00am - 9.20am
|
Session 4: Gastrointestinal Cancer - Colorectal and Anal: The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
|
Dr. Mohamed Sir
Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
9.20am - 9.40am
|
Session 5: Gastrointestinal Cancer - Colorectal and Anal: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
|
Dr. Mai Mostafa
Associate Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
9.40am - 10am
|
Session 6: Melanoma/Skin Cancers: Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047)
|
Dr. Asma El Hassan
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
10am - 10.20am
|
Session 7: Melanoma/Skin Cancers: Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
|
Dr. Ashraf Awad
Associate Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
10.20am - 10.50am
|
Break
|
|
10.50am - 11am
|
Session 8: Sarcoma: Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial
|
Dr. Asma El Hassan
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
11am - 11.10am
|
Session 9: Sarcoma: High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes
|
Dr. Asma El Hassan
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
11.10am - 11.30am
|
Session 10: Central Nervous System Tumors: Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors
|
Dr. Ashraf Awad
Associate Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
11.30am - 11.50am
|
Session 11: Head and Neck Cancer: Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial
|
Dr. Alaaeldin Kanbour
Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
11.50am - 12.10pm
|
Session 12: Genitourinary Cancer - Kidney and Bladder: Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC)
|
Dr. Abdulrahman Zar Gul
Sr. Consultant, Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
12.10pm - 12.30pm
|
Session 13: Genitourinary Cancer - Kidney and Bladder: Avelumab first line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
|
Dr. Abdulrahman Zar Gul
Sr. Consultant, Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
12:30pm - 1pm
|
Break
|
|
1pm - 1.20pm
|
Session 14: Genitourinary Cancer - Kidney and Bladder: Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
|
Dr. Ammar Madani
Associate Consultant Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
1.20pm -1.40pm
|
Session 15: Genitourinary Cancer - Kidney and Bladder: Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial. *
|
Dr. Rajiv Apsani
Specialist Radiation Oncologist, National center for cancer care and research, Hamad medical corporation, Qatar
|
|
1.40pm -2pm
|
Session 16: Care Delivery and Regulatory Policy: Association between Medicaid expansion under the Affordable Care Act and survival among newly diagnosed cancer patients
|
Ms. Wafaa Shehada
Clinical Nurse Specialist, Breast Cancer, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
Ms. Shaikha Mohsen Al-Keldi
Clinical Nurse Specialist, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
2pm - 2.20pm
|
Session 17: Care Delivery and Regulatory Policy: Documentation of goals of care (GOC) by medical oncologists is associated with improved oncology patient end-of-life (EOL) care outcomes.
|
Ms. Asma Mohammad
Clinical Nurse Specialist, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar.
|
|
2.20pm - 2.40pm
|
Session 18: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology: Racial and ethnic disparities among participants in precision oncology clinical studies.
|
Dr. Anas Hamad
Director Pharmacy, National Centre for Cancer Care and Research, Hamad Medical Corporation, Qatar.
|
|
2.40pm - 3pm
|
Closing Remarks
|
Dr. Ussama Al Homsi
Deputy Medical Director, Education, Quality and Research, National Centre for Cancer Care and Research. Hamad Medical Corporation, Qatar
|
